标题
Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis
作者
关键词
-
出版物
Expert Review of Neurotherapeutics
Volume -, Issue -, Pages 1-9
出版商
Informa UK Limited
发表日期
2023-10-16
DOI
10.1080/14737175.2023.2268842
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ublituximab: First Approval
- (2023) Arnold Lee DRUGS
- Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
- (2023) Izanne Roos et al. JAMA Neurology
- Multiple sclerosis: two decades of progress
- (2022) Bruce A C Cree et al. LANCET NEUROLOGY
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
- (2022) Lawrence Steinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple sclerosis progression: time for a new mechanism-driven framework
- (2022) Tanja Kuhlmann et al. LANCET NEUROLOGY
- Rituximab for the treatment of multiple sclerosis: a review
- (2021) Clara Grazia Chisari et al. JOURNAL OF NEUROLOGY
- Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
- (2021) Jeff P Sharman et al. Lancet Haematology
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
- (2021) Maria T. Cencioni et al. Nature Reviews Neurology
- Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions
- (2021) Charles L Bennett et al. Lancet Haematology
- A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- (2020) Edward Fox et al. Multiple Sclerosis Journal
- Vitamin D, smoking, EBV, and long-term cognitive performance in MS
- (2020) Marianna Cortese et al. NEUROLOGY
- Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy
- (2020) Peggy S. Eis et al. Frontiers in Neurology
- Long-term drug treatment in multiple sclerosis: safety success and concerns
- (2020) Dejan Jakimovski et al. Expert Opinion On Drug Safety
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
- (2020) Ludwig Kappos et al. JAMA Neurology
- Ocrelizumab shorter infusion
- (2020) Hans-Peter Hartung Neurology-Neuroimmunology & Neuroinflammation
- The role of B cells in Multiple Sclerosis and related disorders
- (2020) Giancarlo Comi et al. ANNALS OF NEUROLOGY
- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients
- (2019) Amy E. Lovett-Racke et al. JOURNAL OF NEUROIMMUNOLOGY
- A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder
- (2019) Maureen A. Mealy et al. MEDICINE
- Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Matthew Lunning et al. BLOOD
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Multiple sclerosis
- (2018) Alan J Thompson et al. LANCET
- The national incidence of PML in Sweden, 1988–2013
- (2018) Ellen Iacobaeus et al. NEUROLOGY
- Interferon β for Multiple Sclerosis
- (2018) Dejan Jakimovski et al. Cold Spring Harbor Perspectives in Medicine
- A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism
- (2018) Niken M. Mahaweni et al. Scientific Reports
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
- (2016) Jeff P. Sharman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
- (2015) Su-Hyun Kim et al. JAMA Neurology
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients
- (2010) Regina Rendas-Baum et al. QUALITY OF LIFE RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now